Wockhardt dips after FDA observations on Chikalthana plant

At 1200 hours there are pending sell orders for 185,481 shares on NSE and BSE.

Wockhardt is locked in lower circuit of 5% at Rs 551 on NSE with no buyers on the counter after the US regulator said that the company’s Chikalthana Form 483 includes 16 observations.

A combined 780,000 shares change hands on the counter and there are pending sell orders for 185,481 shares on NSE and BSE.

US Food and Drug Administration (FDA) inspectors visited the factory that produces generic copies of the heart tablet Toprol-XL in July, they found urine spilling over open drains, soiled uniforms and mold growing in a raw-material storage area, the Bloomberg report suggests.

Meanwhile, Wockhardt has hired consultants, appointed a new quality supervisor and is working on a better compliance system to address the report on Chikalthana, added report.